About Us

Every time we believed in the power of possibilities, we'd like to think that the world has received some noteworthy creations. And that's precisely what defines the DNA of Themis

We are the seekers. We are the ones always in search of possibilities.
For we know, in every possibility lies an innate, latent power to change lives.

We are

Shri Shantilal D. Patel

Founder

Mission & Vision

"Our Mission" is to benefit patients.

"Our Vision" is to develop targeted medicines that offer patients and physicians better, safer, more cost-effective healthcare.

Infrastructure

By the pioneering efforts of team Themis and a renewed partnership with Gedeon Richter we are on a sustainable growth trajectory. The result is

4 state of the art manufacturing facilities in India
A nationwide stockist network of over 4000 stockists
Operations in over 44 countries

Along the way, we have forged partnerships for development and marketing with many industry leaders, working symbiotically towards a healthier future. We are in business, yes, but we are also in the forefront, and this, is what motivates us to keep going to benefit patients.

Focus Areas

Themis is well known for developing novel formulation and manufacturing APIs. The area of our focus is differentiated parenteral formulations and new drug delivery systems (NDDS) such as life saving drugs like EMAL, relatively painless injection like ETOJET, etc.

EMAL

EMAL contains α-β Arteether, an Artemisinin derivatives indigenously developed in collaboration with CDRI.
It is a first of its kind injectable antimalarial medicine for treatment of severe malaria which is administered ONCE daily.
EMAL is prepared in Arachis oil and is available as 1 and 2ml ampoules (conc. 75 mg/ml)

ETOJET

Etoject injection is the first Etoricoxib pareneteral formulation in the World.
It is a small volume injection, available as 1 ml ampoule (Conc. 90 mg/ml) and is administered intramuscularly.
Being less viscous, it is easily syringable.
Because of the lower volume and less viscous nature of the formulation, it is relatively painless.
It is protected by patent.

AQUADOL

AQUADOL injection contains Diclofenac Sodium
It is a small volume injection, available as 1 ml ampoule (conc. 75 mg/ml) and is administered intramuscularly.
Being less viscous, it is easily syringable.
Because of the lower volume and less viscous nature of the formulation, it is relatively painless

Areas of Innovation and Research

Anti-infective
Antimalarial
Anti-Tuberculosis
Cardiology
Health & Nutrition
Oncology
Ophthalmology
Pain Management

Our Strengths

Partnerships are at the heart of our business. While exploring possibilities in every process, strategy and research, we help our partners excel.

Our people are our real power

For all the innovations we have attained and milestones we have achieved, the real credit goes to our ever-evolving work force. It's our strong R&D team who has made all the difference with their specialized skills and dedication. Our Domestic Marketing team is striving to transform lives with their great talent, while the Export team is taking our endeavours to a new level by supporting the medical fraternity worldwide.

On-time deliveries

Our 4 state-of-the-art manufacturing plants:

Have cutting-edge technology and process-driven manufacturing process
Offer skilled factory technicians, who have adherence to production schedules
Ensure deadline-driven, quality-controlled distribution and delivery support

Ready availability of a large range of innovative formulations

With a growing basket of new products, we have always focused on the core issues of critical therapies. It ensures that our partners focus on market expansion and discover new possibilities.

The benefits of our PPT (Patented Platform Technology):

Incisive products that are breakthroughs
Faster product development cycles
Highly detailed documentation of results and trials

QC policy / Certified Accreditations

We promise unmatched quality by partnering (on CMO basis) with entities that have certified accreditation.
WHO-GMP | EUGMP | PICS